Exocin eye drops

Exocin is a specialized antibacterial medical product containing ofloxacin, widely used for treating external ocular infections. The brand was originally developed by Allergan, an Irish-domiciled pharmaceutical company that has been a long-standing leader in eye care. Exocin has a global presence, with manufacturing operations distributed across multiple countries to serve various regional markets, adhering to strict pharmaceutical safety standards.

Ownership of the brand transitioned through one of the largest mergers in the pharmaceutical industry. In 2020, AbbVie, a leading American biopharmaceutical company, completed the acquisition of Allergan. This move integrated Exocin into AbbVie’s extensive portfolio of medical and aesthetic brands, reinforcing AbbVie's position as a global powerhouse in healthcare. Since the acquisition, AbbVie has remained the ultimate parent company, overseeing the manufacturing and distribution of Exocin worldwide.